Compare Snap Inc (SNAP) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs GeneDx Holdings Corp — how do they compare? Snap Inc trades at $5.89 (market cap $9.83B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: Snap Inc is far larger — about 4.8× GeneDx Holdings Corp's market cap, and Snap Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Snap Inc for 68 Days and GeneDx Holdings Corp for 19 Days on average.
| SNAP | WGS | |
|---|---|---|
Market Cap | $9.83B | $2.04B |
Volume | 28,532,342 | 659,215 |
Sector | Media | Health |
52-Week High | $9.09 | $167.51 |
52-Week Low | $3.93 | $34.51 |
Typical Hold Time | 68 Days | 19 Days |
Enterprise Value | $11.39B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap Inc. (SNAP) trades at $5.865, up 1.12% with a bullish technical signal. Revenue grew to $5.93B in 2025, though net losses persist at -$460M. Recent news highlights AI integration in SPECS glasses via partnerships with NVIDIA and Salesforce. Analyst consensus is mixed with 38% buy ratings and a $7.78 price target.
Outlook: Potential upside exists from AI initiatives and revenue growth, but profitability challenges and high debt ($3.61B) pose risks. The stock's valuation (P/S 1.55) appears reasonable, yet investor caution is warranted amid regulatory pressures and competitive threats.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
